Role of Fibrocytes in the Bronchial Remodelling of Chronic Obstructive Pulmonary Disease (FIBROCHIR)

This study is currently recruiting participants.
Verified October 2013 by University Hospital, Bordeaux
Sponsor:
Information provided by (Responsible Party):
University Hospital, Bordeaux
ClinicalTrials.gov Identifier:
NCT01692444
First received: September 17, 2012
Last updated: October 24, 2013
Last verified: October 2013

September 17, 2012
October 24, 2013
April 2013
April 2014   (final data collection date for primary outcome measure)
Increased number of peri-bronchial and blood circulating fibrocytes gradually in each stages of COPD and compared to control subjects. [ Time Frame: Lung tissues and blood samples will be collected at inclusion visit during surgery (Day 0) ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01692444 on ClinicalTrials.gov Archive Site
  • Characterization of fibrocytes: expression of chemokines receptors, Toll Like Receptors, HLA class II [ Time Frame: Lung tissues and blood samples will be collected at inclusion visit during surgery (Day 0) ] [ Designated as safety issue: No ]
  • Correlation between lung attenuation and the number of fibrocytes [ Time Frame: Assessed one year after inclusion visit (i.e. surgery date =Day 0) ] [ Designated as safety issue: No ]
  • Correlation between plethysmography and the number of fibrocytes. [ Time Frame: Assessed one year after inclusion visit (i.e. surgery date = Day 0) ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Role of Fibrocytes in the Bronchial Remodelling of Chronic Obstructive Pulmonary Disease
Role of Fibrocytes in the Bronchial Remodelling of Chronic Obstructive Pulmonary Disease

Airway remodelling is an abnormal tissue repair following bronchial inflammation, which contributes to none reversible pathological features, such as bronchial and peri-bronchial fibrosis. It also influences the prognosis of Chronic Obstructive Pulmonary Disease (COPD) and its mechanisms remain largely unknown. The role of fibrocytes has been demonstrated in the pathophysiology of asthma, lung fibrosis or pulmonary hypertension. However, the recruitment of blood fibrocytes and their involvement in COPD airway remodelling remain unknown.

The main objective of the study is to analyse the distribution and quantify the number of the peri-bronchial and blood circulating fibrocytes in patients with different stages of COPD compared to control subjects.

Not Provided
Observational
Observational Model: Case Control
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Description:

Lung tissue form surgery such as lobectomy or pneumonectomy,whole blood sample for fibrocytes analysis

Non-Probability Sample

Controls and COPD patients will be recruited during surgical visit or hospitalization in thoracic surgery department before surgery.

Chronic Obstructive Pulmonary Disease
Not Provided
  • COPD
    15 patients with COPD from 1 to 4 according to the GOLD 2011
  • Non smoker Control
    15 patients without COPD and no smoking history
  • Smoker Control
    15 patients without COPD but a smoking history
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
45
April 2015
April 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female aged more than 40 yr
  • Patient needed a thoracic surgery such as lobectomy for cancer or lung transplantation or lung reduction volume surgery.
  • COPD group: diagnostic of COPD and differentiation of the stage from 1 to 4 according to the GOLD guidelines.
  • Control group: subjects with normal lung function testing and no chronic symptoms (cough or expectoration). Subjects will be separated in 2 groups according to smoking history (Never smokers, smokers (former or current) and paired to patients according to age and sex.
  • with a written informed consent

Exclusion Criteria:

  • Subject without any social security or health insurance
  • Asthma, lung fibrosis or idiopathic pulmonary hypertension
  • Chronic viral infections (hepatitis, HIV)
  • Pregnant woman or breastfeeding
  • Subject included for cancer surgery with a Pn0 diagnosis not confirmed after the intervention.
Both
40 Years and older
No
Contact: Matthieu THUMEREL, MD (0)557656009 ext +33 matthieu.thumerel@chu-bordeaux.fr
France
 
NCT01692444
CHUBX 2011/34
No
University Hospital, Bordeaux
University Hospital, Bordeaux
Not Provided
Study Chair: Nicholas MOORE, MD-PhD University Hospital, Bordeaux
University Hospital, Bordeaux
October 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP